Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Account Payables
Amounts the company owes suppliers for goods and services received.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 29.1% from a year ago
Account payables stood at $1.62M at the end of Q1 FY2026, down 29.1% from a year earlier and down 36.5% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.
Context
- Account payables amounted to 4.0% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -29.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.54M USD
- Year-over-year change
- +11.6%
- 4-year CAGR
- +8.9%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.54M | +11.6% |
| FY2024 | 2024-12-31 | 2.28M | +139.1% |
| FY2023 | 2023-12-31 | 953K | -23.9% |
| FY2022 | 2022-12-31 | 1.25M | -30.8% |
| FY2021 | 2021-12-31 | 1.81M | — |
Account Payables vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's Mar 2026 account payables of $1.62M is the 7th highest of the 10 companies compared; the peer median is $2.02M.
- Its year-over-year change of -29.1% is the 5th highest of 10, against a peer median of -32.7%.
- Account payables amounts to 4.0% of total assets for IMDX, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $19.31M | +6.1% | -13.6% | 32.2% | |
| Mar 2026 | $10.02M | +320.4% | +35.6% | 5.2% | |
| Mar 2026 | $2.13M | -64.8% | -21.8% | 1.6% | |
| Mar 2026 | $2.07M | -64.5% | -16.2% | 1.7% | |
| Mar 2026 | $2.02M | -76.9% | +108.5% | 0.8% | |
| Mar 2026 | $1.65M | -14.5% | -14.2% | 0.6% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $1.62M | -29.1% | +26.6% | 4.0% |
| Mar 2026 | $773K | +13.2% | -9.9% | 0.2% | |
| Mar 2026 | $660K | -32.7% | -46.6% | 0.9% | |
| Mar 2026 | $622K | -77.0% | -15.5% | 0.4% | |
| Peer median (excluding IMDX) | $2.02M | -32.7% | -14.2% | 0.9% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.95M | 19.99M | 9.43M | 8.64M | 11.58M |
| Short-term Investments | 904K | 433K | 0 | 0 | 0 |
| Net Receivables | 1.44M | 2.01M | 484K | 1.61M | 1.13M |
| Inventory | 304K | 0 | 0 | 410K | 446K |
| Other Current Assets | 2.94M | 2.12M | 782K | 1.1M | 2.15M |
| Total Current Assets | 39.14M | 25.54M | 10.7M | 11.76M | 15.31M |
| Property, Plant & Equipment (Net) | 8.37M | 10.85M | 5.44M | 2.76M | 2.82M |
| Goodwill | 18.68M | 0 | 0 | 0 | 0 |
| Intangible Assets | 61.72M | 61.63M | 56.6M | 14.61M | 0 |
| Long-term Investments | 0 | 0 | 0 | 1.7M | 607K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.65M | 2.07M | 2.16M | 4.26M | 7.03M |
| Total Non-current Assets | 120.42M | 74.56M | 64.19M | 23.32M | 10.45M |
| Total Assets | 159.56M | 100.09M | 74.89M | 35.08M | 25.76M |
| Account Payables | 1.81M | 1.25M | 953K | 2.28M | 2.54M |
| Short-term Debt | 1.31M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.71M | 4.43M | 4.01M | 2.17M | 2.89M |
| Total Current Liabilities | 14.12M | 12.11M | 7.19M | 7.28M | 12.08M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 76.68M | 45.66M | 45.03M | 37.71M | 43.46M |
| Total Non-current Liabilities | 80.23M | 48.39M | 47.23M | 40.08M | 45.15M |
| Total Liabilities | 94.35M | 60.5M | 54.42M | 47.36M | 57.22M |
| Common Stock | 252.95M | 294.93M | 310.3M | 338.24M | 369.21M |
| Retained Earnings | (187.77M) | (260.68M) | (289.88M) | (350.54M) | (400.76M) |
| Accumulated OCI | 37K | 39K | 49K | 21K | 86K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 65.22M | 39.59M | 20.47M | (12.27M) | (31.46M) |
| Total Debt | 5.68M | 3.54M | 2.87M | 3.66M | 3.5M |
| Net Debt | (27.27M) | (16.45M) | (6.56M) | (4.97M) | (8.09M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.